SynAct Pharma AB

Stockholm Stock Exchange SYNACT.ST

SynAct Pharma AB Operating Cash Flow for the year ending December 31, 2023: USD -9.89 M

SynAct Pharma AB Operating Cash Flow is USD -9.89 M for the year ending December 31, 2023, a 11.93% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

SynAct Pharma AB Operating Cash Flow for the year ending December 31, 2022 was USD -11.23 M, a -56.88% change year over year.
SynAct Pharma AB Operating Cash Flow for the year ending December 31, 2021 was USD -7.16 M, a -77.64% change year over year.
SynAct Pharma AB Operating Cash Flow for the year ending December 31, 2020 was USD -4.03 M, a -134.83% change year over year.
SynAct Pharma AB Operating Cash Flow for the year ending December 31, 2019 was USD -1.72 M, a 37.03% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Stockholm Stock Exchange: SYNACT.ST

SynAct Pharma AB

CEO	Mr. Jeppe Ovli Ovlesen EE, MBA
IPO Date	July 11, 2016
Location	Sweden
Headquarters	Scheelevägen 2
Employees	5
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranous glomerulonephritis. It has a partnership with the University Of Örebro to study the reduction of inflammation in vascular disease. The company was founded in 2012 and is headquartered in Lund, Sweden.

Key trends

Past 5 years